CORRESP Filing
Armata Pharmaceuticals, Inc.
Date: Aug. 20, 2025 · CIK: 0000921114 · Accession: 0001104659-25-080910
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289585
Letter
VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Armata Pharmaceuticals, Inc. (the "Company") Registration Statement on Form S-3 (File No. 333-289585) (the "Registration Statement")
Re:
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the "Securities Act"), the Company hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Friday, August 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Andrew C. Marmer of Willkie Farr & Gallagher LLP, at (212)-728-8847 or the undersigned at (310)-626-0538. Please also call Andrew C. Marmer as soon as the Company's Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter.
Sincerely,
ARMATA PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm August 20, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Armata Pharmaceuticals, Inc. (the "Company") Registration Statement on Form S-3 (File No. 333-289585) (the "Registration Statement") Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the "Securities Act"), the Company hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Friday, August 22, 2025, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. If you have any questions regarding this request, please contact our outside counsel, Andrew C. Marmer of Willkie Farr & Gallagher LLP, at (212)-728-8847 or the undersigned at (310)-626-0538. Please also call Andrew C. Marmer as soon as the Company's Registration Statement on Form S-3 has been declared effective. Thank you for your attention to this matter. Sincerely, ARMATA PHARMACEUTICALS, INC. By: /s/ David House Name: David House Title: Senior Vice President, Finance and Principal Financial Officer cc: Andrew C. Marmer, Willkie Farr & Gallagher LLP